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Abstract
Introduction: Older populations are more at risk of problems such as temporal arteritis or
polymyalgia rheumatica, and these conditions are often first diagnosed in general practice, with usual
ongoing care and long-term treatment with oral steroids. These inflammatory conditions are also
potential risk factors for other complicating presentations such as transient ischaemic attacks, but the
precise comorbid links and how these might influence clinical management in general practice are
unclear.
Case presentation: An 82-year-Caucasian woman living alone requested a home visit after a single
episode of speech disturbance and disorientation which lasted 15 minutes. This occurred 2 weeks
after cessation of her oral prednisolone for temporal arteritis, which was clinically diagnosed in 2006
and later confirmed by a biopsy. She also had a past medical history of ischaemic heart disease based
on symptom presentation and an abnormal ECG in October 2005, but no other relevant risk factors
for cardiovascular disease.
Conclusions: Transient ischaemic attack is an alternative presentation or complication of an
inflammatory disease such as temporal arteritis. The clinical implications of this case relate to the
assessment of comorbid risk in TA and in tailoring the drug treatment. In using prednisolone
treatments in such patients, general practitioners will need to carefully titrate drug doses and the
duration of treatment to prevent complications. Clear evidence for the precise type of management
remains to be established.
Introduction
Temporal arteritis (TA) and polymyalgia rheumatica are
inter-related inflammatory disorders, which are mana-
ged over long term in general practice. The highest rates
for new onset diagnosis for these conditions are in the
age group 70 years and over, and in the general practice
population are estimated at 6 per 10,000 person
consulting years for temporal arteritis and 22 per
10,000 person consulting years for polymyalgia rheu-
matica, with a female to male ratio of around 2 to 1 [1].
The diagnosis of each is based primarily on clinical
features at presentation, and supported additionally by
erythrocyte sedimentation rate (ESR), thrombocytosis
and biopsy of temporal artery [2,3]. The recommended
treatment for both conditions is long-term oral pre-
dnisolone [4].
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In temporal arteritis, immediate and high dose (60 mg
daily) treatment is recommended for a month in a person
with suspected TA to prevent the high risk of ocular
complications [5], which can be tapered down gradually
after the first month. The duration of therapy can last
many years, but it is unclear as to how this condition may
relapse according to the dose of prednisolone. There have
been specific and isolated reports of other comorbid
complications, which include cerebrovascular accidents
[6] and cardiovascular events [7]. Despite these known
complications, in general practice where most of these
patients are managed over longer term, current approaches
to drug dose management and prevention of complica-
tions seem empirical.
Case presentation
A support carer requested a home visit on behalf of her
client, who is a-82-year Caucasian lady living alone. Three
days previously, in the presence of the support carer, she
had had acute symptoms last 15 minutes during which she
was alert but disorientated, could not express her speech,
and afterwards found that writing had become difficult.
There was no loss of consciousness and neither was there
any weakness or paraesthesia in any of her limbs. She
improved over a few hours, and on the day of the visit, she
felt as if she was back to normal. She diagnosed herself as
having had a transient ischaemic attack.
On closer questioning, she explained that for several years
she had been on prednisolone for her eye problems
(temporal arteritis) and 2 weeks previously this drug had
been stopped after a period of reduction in the dose under
GP supervision. She had been keen to come off them as
she had suffered from dyspeptic symptoms.
On the day of the visit, her clinical examination was
unremarkable, with the exception of a blood pressure
measurement of 160/80. However her home BP recordings
were in normal range. She is right handed, was alert and
orientated, and her specific cardiac (e.g. sinus rhythm, no
murmurs or carotid bruits) and neurological system (e.g.
speech, power, writing) examinations were normal. There
was no temporal artery tenderness.
Past medical history from her clinical records showed that
she had been diagnosed in October 2005 with ischaemic
heart disease (IHD) on the basis of atypical chest
symptoms and an abnormal ECG showing inferior
ischaemic changes. Her initial treatment for this was
nitrolingual spray and aspirin, but she had refused a statin.
In November 2006, she presented with visual symptoms
and pain in her jaw and an ESR of 36, and was commenced
on oral steroid with a provisional diagnosis of temporal
arteritis. She responded well with resolution of her
symptoms to this initial treatment, but in early 2007
wanted to reduce her dose of prednisolone because of
dyspeptic symptoms. However some of symptoms
returned and she was referred to the ophthalmology
service for further confirmation of the diagnosis. Her
temporal artery biopsy result came back as showing
‘inflammatory changes’ and together with her symptoms
including the partial loss of vision in her left eye; she was
given a formal diagnosis of TA and recommended to
continue the prednisolone. To this treatment, she was
given a proton inhibitor, and by now she had stopped
using her nitrolingual spray.
She was married but had no children, never smoked and
always been tea-total. She retired as a book-keeper many
years ago and has carer support because of mobility
problems, but she was ambulant around her house.
Based on her clinical history a diagnosis of transient
ischaemic attack secondary to withdrawl of treatment for
temporal arteritis was made, and with her agreement
prednisolone 30 mg daily was re-commenced. Follow up
at 1 week was arranged to consider referral for TIA clinic
depending on her symptoms and blood results. During the
home visit, routine blood samples were collected, which
were later reported as an ESR of 27 and random
cholesterol of 5.4.
Her clinical records were reviewed 2 weeks after the first
visit, and showed that she had had no further symptoms, a
referral to TIA clinic and simvastatin treatment had been
offered, but both options were refused. Her prednisolone
dose was now down to a maintenance dose of 7.5 mg
daily.
Discussion
This case illustrates the interface between the management
approaches to single diseases and how comorbidity in the
older person may weave complex relationships that
influence the management as clinicians in primary care
or otherwise.
Despite her lack of risk factors for cardiovascular disease,
her first significant diagnosis was based on atypical
symptoms and ECG signs. Whilst it is possible that this
was a mis-diagnosis, the question in view of the later
diagnosis of TA, is whether these symptoms heralded the
underlying development of TA. There have been case
reports in literature, which support the link in symptoms
of angina and underlying arteritis [8].
She then presented with symptoms more consistent with
TA but with a marginal increase in ESR, and then notably
there was good therapeutic response to treatment with oral
prednisolone. It was the clinical suspicion (specifically jaw
pain) and good response to the drug intervention that
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initially supported the diagnosis of TA, despite the
marginally raised ESR. In literature and guidelines, an
ESR of over 50 and lymphocytosis, have been recom-
mended as supporting a diagnosis of TA [2,3]. However,
this case highlights that clinical skills and therapeutic
response are as important as laboratory tests in the
decision-making process, when gold standard investiga-
tion such as biopsy in TA is not feasible in all patients.
The clinical features that required the home visit were
classical presentation of a transient neurological deficit, in
the context of withdrawal of oral prednisolone. Here the
challenge to clinical decision-making in a person of this
age was on whether this was an ischaemic event with
atherosclerotic basis or an event with inflammatory TA
basis. She had a record of possible IHD and yet had no
relevant risk factors with a return report of a marginally
raised random cholesterol levels. So an immediate
response would have been to arrange a TIA clinic
assessment that focused on the management of athero-
sclerosis pathway or instead the alternative management
of the acute event with the use of oral prednisolone. The
decision made at home visit was to treat as if there was a
secondary TA event and to follow-up with results and
symptom re-assessment.
The other key issues raised are the dose and duration of
oral prednisolone therapy in patients with TA, in both in
the initial and continuing phases. Current literature
recommends high dose (60 mg daily) for one month in
the new event of TA, but in this case had had recent
treatment lasting two-and-half years and she also had a
history of possible side effects, resulting in the decision to
prescribe 30 mg prednisolone daily [3]. Current consensus
also advises that the course of TA can last months or years
and that there should be a gradual tapering down of the
dose [9]. Yet, it is unclear as to what the minimum dose of
prednisolone might be indicated for patients with
comorbidity, for example diabetes, or those who suffer
associated side effects. Furthermore, how the dose of
prednisolone can be tailored over time and how the flare-
ups of TA disease are monitored, remains to be estab-
lished. The crucial learning point in this case is arguably
that in the single pursuit of TA and decreasing therapy, this
patient may have suffered an associated risk and compli-
cating comorbidity of an event such as transient ischaemic
or neurological deficit.
Finally, developments in science and the rawness of
information in general practice encounters have to be
placed in the context of the patient decision, which is final.
So this patient had her own views on the choice and dose
of therapy, on whether she was referred or not, and
whether she consented to the guidelines that clinicians are
recommended to follow.
Conclusions
Transient ischaemic attack is an alternative presentation or
complication of an inflammatory disease such as temporal
arteritis, and there have been case reports of cardiac
presentations of TA. The clinical implications of this case
relate to the assessment of comorbid risk in TA and in
tailoring the drug treatment. In using prednisolone
treatment in such patients, general practitioners will need
to carefully titrate drug doses and the duration of treatment
to prevent such complications, but clear evidence for the
precise type of management remains to be established.
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